Pipeline

BP1209

  1. A new platform of personalized neoantigen cancer vaccines directed by checkpoint inhibitor antibodies to improve cancer immunity
図1

BP1209 is a proprietary, advanced cancer vaccine which targets tumor-specific neoantigens for the personalized treatment of cancer patients. The BP1209 vaccine is delivered as a molecular complex of patient-specific neoantigen peptides and immune-checkpoint inhibitor antibody such as anti-PD-L1 and anti-CD40 antibodies. The antibody directs the vaccine complex to dendritic cells (DCs), and enhances the cellular uptake of vaccine as well as the antigen-specific T cell priming by suppressing PD-1/PD-L1 signaling or CD40 activation.

The neoantigen peptides consists of three modules: HLA-class I and -class II neoantigen epitopes, and an IgG-binding motif. The peptides non-covalently bind Fc domain of IgG, and self-assemble the antibody-vaccine complex without any chemical reaction which enables individual synthesis and manufacturing fully personalized neoantigen vaccine. In this poster, authors demonstrate BP1209 strongly enhances antigen-specific immune responses and improves antitumor efficacy using cancer neoantigen. BrightPath has developed in-house bioinformatic algorithms to identify highly immunogenic neoantigens from cancer patients. The new vaccine platform of BP1209 in combination with BrightPath’s algorism to identify high quality neoantigens provides an ideal option to improve neoantigen vaccine therapy.

Personalized neoantigen cancer vaccine assembled on DC targeting antibody improves cancer immunity. AACR 2022
VIEW POSTER

A new platform of personalized neoantigen cancer vaccines directed by checkpoint inhibitor antibodies to improve cancer immunity. ESMO 2021
VIEW POSTER

close